PMID- 12188098
OWN - NLM
STAT- MEDLINE
DCOM- 20030312
LR  - 20190910
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 26
IP  - 4
DP  - 2002 May
TI  - Nefazodone treatment of dysthymic disorder an open, long-term, prospective pilot 
      study.
PG  - 671-6
AB  - Dysthymic disorder, described by the Diagnostic and Statistical Manual of Mental 
      Disorders--4th edition (DSM-IV) criteria as a chronically depressed mood that 
      occurs most of the day more days than not for at least 2 years and has a lifetime 
      prevalence rate of approximately 3.3% [Gwirtsman, 1994. Psychopharmacol. Bull. 30 
      (1994) 45.]. This disorder, which is disabling, often goes unrecognized and its 
      sufferers are often undertreated, but recent evidence has suggested that people 
      with dysthymia may respond to antidepressant treatment. Based on effective 
      outcomes in previous studies using fluoxetine (a 5-HT reuptake inhibitor) and 
      ritanserin (a 5-HT2A antagonist), it was hypothesized that nefazodone, which is 
      both a serotonin (5-HT) reuptake inhibitor (rather weak) and a 5-HT2A receptor 
      antagonist, may provide an effective treatment for patients with dysthymic 
      disorder. Six participants completed this 24-week pilot trial. A decrease in the 
      Hamilton Rating Scale for Depression (HAM-D) scores was observed from baseline to 
      Week 24, although most changes occurred in the first 4 weeks of participation. 
      There was an improvement in anxiety symptomatology, both physiological and 
      psychological. General functioning did not improve as observed by Global 
      Assessment of Functioning Scale (GAF) scores. There may be some benefit to 
      nefazodone for treatment of dysthymia, as indicated by positive results on HAM-D, 
      Hamilton Anxiety Scale (HAM-AD), and Hopkins Symptom Checklist (HCL) scores 
      within the first 4 weeks; however, it is possible that such dramatic results may 
      be due to entry into the study alone, and not to medication.
FAU - Dursun, Serdar M
AU  - Dursun SM
AD  - Psychopharmacology Research Unit, Department of Psychiatry, Dalhousie University, 
      QEII Health Sciences Centre, Halifax, Nova Scotia, Canada. sdursun@is.dal.ca
FAU - Bird, Diane
AU  - Bird D
FAU - Ronson, Karen E
AU  - Ronson KE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Piperazines)
RN  - 0 (Triazoles)
RN  - 59H4FCV1TF (nefazodone)
SB  - IM
MH  - Adult
MH  - Dysthymic Disorder/*drug therapy/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Piperazines
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Triazoles/*therapeutic use
EDAT- 2002/08/22 10:00
MHDA- 2003/03/13 04:00
CRDT- 2002/08/22 10:00
PHST- 2002/08/22 10:00 [pubmed]
PHST- 2003/03/13 04:00 [medline]
PHST- 2002/08/22 10:00 [entrez]
AID - S0278-5846(01)00316-5 [pii]
AID - 10.1016/s0278-5846(01)00316-5 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):671-6. doi: 
      10.1016/s0278-5846(01)00316-5.